Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ: IONS )

29.57 UNCHANGED
Streaming Delayed Price Updated: 11:40 AM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 181,546
Open 29.38
Bid (Size) 29.53 (3)
Ask (Size) 29.61 (1)
Prev. Close 29.57
Today's Range 28.87 - 29.90
52wk Range 23.95 - 52.34
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis to hold first quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead. 
Via Benzinga

Performance

YTD
-14.76%
-14.76%
1 Month
-8.37%
-8.37%
3 Month
-14.19%
-14.19%
6 Month
-23.73%
-23.73%
1 Year
-30.34%
-30.34%

More News

Read More
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Ionis to host expert panel discussion on sHTG
From Ionis Pharmaceuticals, Inc.
Via Business Wire
What Analysts Are Saying About Ionis Pharmaceuticals Stock
Via Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Via Benzinga
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
Via Benzinga
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Via Benzinga
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
From Ionis Pharmaceuticals, Inc.
Via Business Wire
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis Pharma Beats Expectations for Q4
Via The Motley Fool
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
Via Benzinga
Ionis reports fourth quarter and full year 2024 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to hold fourth quarter and full year 2024 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Via Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
Via Investor's Business Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.